Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Tisagenlecleucel

Immune effector cell-associated neurotoxicity syndrome

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wesson W, et al. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study. Transplantation and Cellular Therapy 30 (Suppl.): S206-S207, No. 2, Feb 2024. Available from: URL: https://dx.doi.org/10.1016/j.jtct.2023.12.268 [Abstract] Wesson W, et al. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study. Transplantation and Cellular Therapy 30 (Suppl.): S206-S207, No. 2, Feb 2024. Available from: URL: https://​dx.​doi.​org/​10.​1016/​j.​jtct.​2023.​12.​268 [Abstract]
Metadaten
Titel
Tisagenlecleucel
Immune effector cell-associated neurotoxicity syndrome
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55025-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Tozinameran

Case report

Goserelin

Case report

Immune-globulin

Case report

Cabergoline